Clinical Trial Detail

NCT ID NCT01358877
Title A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

Her2-receptor positive breast cancer

Therapies

Pertuzumab

Epirubicin

Cyclophosphamide

Paclitaxel

Docetaxel

Trastuzumab

Fluorouracil

Carboplatin

Doxorubicin

Age Groups: senior adult

Additional content available in CKB BOOST